← Leaderboards
Nicholas James Leeper
Stanford University
$11,709,141
Attributed
$13,522,557
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,522,557 · 7
By mechanism
R35$6,207,726 · 2
R01$3,491,170 · 2
T32$3,369,246 · 1
K08$399,573 · 1
F32$54,842 · 1
Top collaborators
- Philip S Tsao8 shared
- Ronald L Dalman2 shared
Most similar at Stanford University
Same institution · by research overlap
- David A. Benaron$15,666,167
- Scott Dexter Boyd$18,651,021
- Peter Poon-Hang Lee$6,837,790
- Debashis Sahoo$5,634,745
- Harry Bernard Greenberg$91,083,131
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesVascular DiseasesUnited StatesUnited States National Institutes Of HealthBlood VesselsResearch PersonnelMissionCellsAtherogenesisNovel TherapeuticsAtherosclerosisPhenotypeLeadHeart DiseasesSmooth Muscle MyocytesInsightGeneticBiologyGrowthPreventProgramsExcisionMyocardial InfarctionPathway Interactions
Grant awards (27)
The role of cancer in cardiovascular disease$1,102,957
R35 · FY2025 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$527,847
T32 · FY2025 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$837,017
R35 · FY2024 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$254,323
T32 · FY2024 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$853,998
R35 · FY2023 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$479,305
T32 · FY2023 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$853,792
R35 · FY2022 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$462,664
T32 · FY2022 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$853,512
R35 · FY2021 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$436,311
T32 · FY2021 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$853,390
R35 · FY2020 · HL · contact PI
T32 Training Program in Mechanisms and Innovation in Vascular Disease$436,039
T32 · FY2020 · HL
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosis$853,060
R35 · FY2019 · HL · contact PI
Mechanisms and Innovation in Vascular Disease$379,641
T32 · FY2019 · HL
The paradoxical role of CDKN2B in blood vessel sprouting and maturation$468,421
R01 · FY2018 · HL · contact PI
The role of CDKN2B in efferocytosis and atherosclerosis$403,644
R01 · FY2018 · HL · contact PI
Mechanisms and Innovation in Vascular Disease$393,116
T32 · FY2018 · HL
The paradoxical role of CDKN2B in blood vessel sprouting and maturation$466,580
R01 · FY2017 · HL · contact PI
The role of CDKN2B in efferocytosis and atherosclerosis$403,644
R01 · FY2017 · HL · contact PI
The paradoxical role of CDKN2B in blood vessel sprouting and maturation$464,883
R01 · FY2016 · HL · contact PI
The role of CDKN2B in efferocytosis and atherosclerosis$403,644
R01 · FY2016 · HL · contact PI
The paradoxical role of CDKN2B in blood vessel sprouting and maturation$476,710
R01 · FY2015 · HL · contact PI
The role of CDKN2B in efferocytosis and atherosclerosis$403,644
R01 · FY2015 · HL · contact PI
The role of CDKN2B in AAA disease$133,191
K08 · FY2014 · HL · contact PI
The role of CDKN2B in AAA disease$133,191
K08 · FY2013 · HL · contact PI
The role of CDKN2B in AAA disease$133,191
K08 · FY2012 · HL · contact PI
The role of the apelin-APJ pathway in vascular wall disease$54,842
F32 · FY2008 · HL · contact PI